Stryker Corporation Stock Coming Through With Growth

Even with pricing worries and weak spine results, Stryker is among the fastest-growing large med-techs

Jul 18, 2014 at 10:22AM

Stryker (NYSE:SYK) has been a fairly strong stock this year, and why not? The company addresses several attractive markets within med-tech and shown a willingness (and capability) to effectively deploy capital toward business-building M&A transactions. Although price weakness, particularly in ortho, is a concern and the stock's valuation isn't a screaming bargain, Stryker likely won't be a bad place to be relative to the sector.

No blowout, but a good enough Q2
Stryker reported revenue growth of nearly 7% this quarter, just slightly ahead of expectations, and a "same-day" organic sales growth rate of 6.3%. Though it is still relatively early in the earnings reporting cycle, that is almost certainly going to be one of the strongest growth rates for the large med-tech sector this quarter and testament to Stryker's leverage to growth markets within med-tech.

Orthopedics revenue rose more than 6% this quarter, as 2.5% growth in major joint recon was sweetened with 11% growth in trauma and extremities. That recon performance is the worst so far of the companies that have reported (Johnson & Johnson was up closer to 3% and Biomet was up 4%), but it was fairly close to expectation. U.S. hips and knees did pretty well (up 6% and 7%, respectively), but the OUS business remains challenged (down 3% and 6%) and pricing remains more challenging than analysts had been expecting (down 3% and in line with Johnson & Johnson's comments).

Medsurg was up 9%, with Endoscopy leading the way with growth of over 17%. Even without the benefit of acquisitions, Endoscopy would have still grown about 9% and Instruments grew more than 7% with the reintroduction of the Neptune waste management system (and apparently taking share back from Zimmer). Medical was up about 4% and management noted that overall hospital demand for equipment is still fairly soft.

Neuro/Spine was mixed – overall revenue was up 4%, with Neuro up more than 8% and Spine down almost 2%. This is the third straight quarter of sequential growth erosion in the spine business and the company is hurting not only from a lack of scale (particularly in minimally invasive) but a loss of reps.

Below the revenue line, Stryker's performance was mixed but with a positive lean. Gross margin was disappointing-down 150bp and more than a half point below expectations – as lower pricing took a bite. Management did meaningfully better on operating expenses (particularly SG&A), though, and operating income rose 2%, beating estimates by about 2% and the operating margin was 40bp higher than the Street expected.

An active acquirer and likely to remain so
Stryker has long been willing to acquire what it needs, wants, and doesn't have the patience to build on its own. The acquisition of Boston Scientific's neuro business has already been a big win for the company and while the MAKO acquisition has yet to really hit its stride, management remains confident in the long-term potential of robotics in orthopedic surgery (and will be introducing new hip and knee implants for the system in 2015).

Most recently the company acquired Small Bone Innovations, a significant player in lower extremities with the STAR total ankle. While I was disappointed that Stryker acquired SBI, in part due to what I believe will be declining momentum in the ankle business and also due to my wish to Stryker acquire Wright Medical Group (which I own), I can't argue that the acquisition won't meaningfully improve the company's position in lower extremity recon.

Looking ahead, Stryker is likely not done yet. Management has mentioned a desire for more scale in the spine business on more than one occasion and either NuVasive or Globus would fit the bill. Stryker definitely needs more scale in spine to compete effectively with Johnson & Johnson and Medtronic, and either target would significantly upgrade the business.

I also expect Stryker to at least consider Smith & Nephew (NYSE:SNN) again. With Medtronic acquiring Covidien, I don't see them as a likely bidder for Smith & Nephew and adding scale in major joints and sports medicine/arthroscopy, as well as adding the wound care business, would fit the current themes in the med-tech space. What's more, with Zimmer looking to acquire Biomet, this could be a good time for a large deal; large deals almost always bring disruptions and dealing with those while another large rival is going through the same challenges may mitigate the damage.

The bottom line
Stryker looks like an OK, but not great, investment prospect today. I definitely like its above-average growth and the shares do not look expensive on forward sales, but the long-term cash flow outlook is not quite strong enough to make it a strong buy. I consider Stryker to be a comparatively good option in a sector that doesn't offer a lot of bargains, and a good company for the long term, but it's hard to get really excited about the share price at today's level.

Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted this emerging technology is threatening his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. Find out how you can cash in on this technology before the crowd catches on, by jumping onto one company that could get you the biggest piece of the action. Click here to access a FREE investor alert on the company we're calling the "brains behind" the technology.

Stephen D. Simpson, CFA owns shares of Wright Medical Group. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers